Type V Glycogen Storage Disease

Updated: May 02, 2022

Author: Isaac Omolade Ogunmola, MBBS; Chief Editor: George T Griffing, MD

Overview

Practice Essentials

A glycogen storage disease (GSD) is the result of an enzyme defect. These enzymes normally catalyze reactions that ultimately convert glycogen compounds to glucose. Enzyme deficiency results in glycogen accumulation in tissues. In many cases, the defect has systemic consequences, but in some cases, the defect is limited to specific tissues. Most patients experience muscle symptoms, such as weakness and cramps, although certain GSDs manifest as specific syndromes, such as hypoglycemic seizures or cardiomegaly.

The diagram below illustrates metabolic pathways of carbohydrates.

Metabolic pathways of carbohydrates.

The following list contains a quick reference for 8 of the GSD types:

0 - Glycogen synthase deficiency
Ia - Glucose-6-phosphatase deficiency (von Gierke disease)
II - Acid maltase deficiency (Pompe disease)
III - Debranching enzyme deficiency (Forbes-Cori disease)
IV - Transglucosidase deficiency (Andersen disease, amylopectinosis)
V - Myophosphorylase deficiency (McArdle disease)
VI - Phosphorylase deficiency (Hers disease)
VII - Phosphofructokinase deficiency (Tarui disease)

Although at least 14 unique GSDs are discussed in the literature, the 4 that cause clinically significant muscle weakness are Pompe disease (GSD type II, acid maltase deficiency), Cori disease (GSD type III, debranching enzyme deficiency), McArdle disease (GSD type V, myophosphorylase deficiency), and Tarui disease (GSD type VII, phosphofructokinase deficiency). One form, von Gierke disease (GSD type Ia, glucose-6-phosphatase deficiency), causes clinically significant end-organ disease with significant morbidity. The remaining GSDs are not benign but are less clinically significant; therefore, the physician should consider the aforementioned GSDs when initially entertaining the diagnosis of a GSD. Interestingly, GSD type 0 also is described and is a disorder causing glycogen deficiency due to defective glycogen synthase.

These inherited enzyme defects usually present in childhood, although some, such as McArdle disease and Pompe disease, have separate adult-onset forms. In general, GSDs are inherited as autosomal recessive conditions. Several different mutations have been reported for each disorder.[1]

Diagnosis

Diagnosis depends on findings from patient history and physical examination, creatine kinase testing, muscle biopsy, electromyelography, and ischemic forearm testing. Biochemical assay for enzyme activity is the method of definitive diagnosis.

Myophosphorylase, the deficient enzyme in McArdle disease, is found in muscle tissue. Myophosphorylase deficiency causes muscle cramps, pain, and stiffness. One hallmark of McArdle disease is weakness with exertion. Proximal muscle weakness may progress with time, and no specific treatment exists.

Management

Unfortunately, no specific treatment or cure exists for GSDs, although diet therapy may be highly effective at reducing clinical manifestations. In some cases, liver transplantation may abolish biochemical abnormalities. Active research continues.

Patient education

Genetic counseling is appropriate for all individuals with a genetic disorder.

Pathophysiology

The phenotype of the individual with GSD results from an enzyme defect. Carbohydrate metabolic pathways are blocked, leading to excess glycogen accumulation in affected tissues and/or disturbances in energy production. Several gene mutations have been described.[1]

Fatty acids and glucose serve as substrates for energy production. With intense exercise, glucose from glycogen stores in muscle becomes the predominant resource. Fatigue develops when the glycogen supply is exhausted.[2, 3] Each GSD represents a specific enzyme defect, and each enzyme is in specific, or most, body tissues. Myophosphorylase is found in muscle. Hypoglycemia is not an expected finding because liver phosphorylase is not involved.

GSD type V is an autosomal recessive disease resulting from mutations in the PYGM gene that encodes for the muscle isoform of glycogen phosphorylase (myophosphorylase). Heterozygotes usually do not manifest clinical features of the disease.[1]

Epidemiology

International statistics

Herling and colleagues studied the incidence and frequency of inherited metabolic conditions in British Columbia. GSDs are found in 2.3 children per 100,000 births per year. The prevalence of GSD type V is estimated to be around 1 in 100,000–140,000 persons. [1]

Age-related demographics

In general, GSDs present in childhood. Later onset correlates with a less severe form. Consider Pompe disease if onset is in infancy.

The majority of patients with McArdle disease present in the second to third decade of life.

Cheraud and colleagues report two unique cases of McArdle disease presenting in individuals in their seventies. Physicians should have clinical suspicion regardless of age of presentation.[4]

Prognosis

The life expectancy of patients with McArdle disease is typically not affected.[1] Pregnancy and childbirth outcomes are relatively unaffected by the disease.[5]

Morbidity/mortality

Immediate morbidity arises from severe exercise intolerance.

Complications

There are potential anesthetic and perioperative risks.[6]

Presentation

History

Consider the following in the history:

Age at onset of symptoms depends on enzyme activity levels. Initial symptoms are cramps, fatigue, and pain after exercise.[7]
Because severity depends on enzyme activity, individual presentation is unique.
The rate of rise in oxygen consumption per unit time (VO2) is relative to work rate increases.
Some adults develop a progressive proximal weakness.
Some adults develop a fixed motor weakness.
The disorder has a unique "second-wind" phenomenon.[8] If a patient nearing fatigue slows exercise to a tolerable level, a point exists at which exercise may be increased again without previous symptoms[9] . According to Porcelli and colleagues, this phenomenon may be secondary to increased adrenergic response to exercise, influx of glucose, free fatty acids, and other substrates for muscle metabolism.[10]
Burgundy-colored urine is usually reported in patients but is not always present. It is thought to be a result of rhabdomyolysis after intense exercise.
Jones and colleagues report an unusual presentation of atypical chest pain and chronic troponinemia associated with hypertrophic cardiomyopathy among family members.[11]

Physical Examination

Physical examination is usually unremarkable in most patients. About 25% of patients may present with evidence of muscle hypertrophy. Proximal muscle wasting and weakness may be seen older patients.[5]

Consider the following in the physical examination:

Diagnosis is suggested by patient history.
Clinical findings may be absent upon physical examination.
Muscle strength and reflexes may be normal.
In later adult life, persistent weakness and muscle wasting may be present.
When clinical suspicion is present, diagnostic testing includes the ischemic forearm test, laboratory analysis, and electromyography.
About 10% of patients with GSD V may present with acute renal failure.[5]

DDx

Differential Diagnoses

Workup

Laboratory Studies

Obtain a creatine kinase level in all cases of suspected GSD. Creatine kinase levels are elevated in more than 90% of patients with McArdle disease. Bruno and colleagues report a case of elevated creatine kinase on routine screening as the only sign of McArdle disease in a 13-year-old boy.[12]

Because hypoglycemia may be found in some types of GSD, fasting glucose testing is indicated. Hypoglycemia is of concern and may lead to hypoglycemic seizures.

Urine studies are indicated because myoglobinuria may occur in some patients with GSDs.

Hepatic failure occurs in some patients with GSDs. Liver function studies are indicated. In general, the liver contains little myophosphorylase.

Myoglobinuria is found in 50% of patients after exercise.

Biochemical assay is required for definitive diagnosis. Phosphorylase reaction is absent.

Other Tests

Ischemic forearm test

The ischemic forearm test is an important tool for diagnosis of muscle disorders. The basic premise is an analysis of the normal chemical reactions and products of muscle activity. Obtain consent before the test.
First instruct the patient to rest. Position a loosened blood pressure cuff on the arm, and place a venous line for blood samples in the antecubital vein.
Obtain blood samples for the following tests: creatine kinase, ammonia, and lactate. Repeat in 5-10 minutes.
Obtain a urine sample for myoglobin analysis.
Immediately inflate the blood pressure cuff above systolic blood pressure and have the patient repetitively grasp an object, such as a dynamometer. Instruct the patient to grasp the object firmly, once or twice per second. Encourage the patient for 2-3 minutes, at which time the patient may no longer be able to participate. Immediately release and remove the blood pressure cuff.
Obtain blood samples for creatine kinase, ammonia, and lactate immediately and at 5, 10, and 20 minutes.
Collect a final urine sample for myoglobin analysis.

Interpretation of ischemic forearm test results

With exercise, carbohydrate metabolic pathways yield lactate from pyruvate. Lack of lactate production during exercise is evidence of a pathway disturbance, and an enzyme deficiency is suggested. In such cases, muscle biopsy with biochemical assay is indicated.
Healthy patients demonstrate an increase in lactate of at least 5-10 mg/dL and ammonia of at least 100 mcg/dL. Levels will return to baseline after the exercise is stopped.
If neither level increases, the exercise was not strenuous enough and the test is not valid.
Increased lactate at rest (before exercise) is evidence of mitochondrial myopathy.
Failure of lactate to increase with ammonia is evidence of a GSD resulting in a block in carbohydrate metabolic pathways. Not all patients with GSDs have a positive ischemic test result.
Failure of ammonia to increase with lactate is evidence of myoadenylate deaminase deficiency.
If a patient has McArdle disease, the ischemic forearm test results are positive.

Electromyography

In contrast to most GSDs, findings upon electromyography may be normal.
Findings from electromyography of resting muscle are normal.
Electrical activity is absent during contracture.
Repetitive nerve stimulation at low frequency (2 Hz) does not demonstrate an abnormal response, although repetitive stimulation at high frequency (15 Hz) may produce a decrement with contracture formation.
Single-fiber electromyography may reveal increased jitter.

Procedures

Muscle biopsy is necessary for assay of muscle enzyme activity.

Muscle biopsy findings may reveal fiber size variability, positive subsarcolemmal blebs with periodic acid-Schiff stain, and intermyofibril vacuoles. Felice and colleagues reported selective atrophy of type 1 muscle fibers.[13]

Treatment

Medical Care

In general, no specific treatment exists for GSDs.

In some cases, diet therapy is helpful. Meticulous adherence to a dietary regimen may reduce liver size, prevent hypoglycemia, help with reduction in symptoms, and allow for growth and development. A high-protein diet may increase exercise tolerance in some cases, although this practice is controversial.[14]
Zingone and colleagues demonstrated the abolition of the murine clinical manifestations of von Gierke disease with a recombinant adenoviral vector.[15] These findings suggest that corrective gene therapy for GSDs may be possible in humans.
An encouraging study by Bijvoet and colleagues provides evidence of successful enzyme replacement for the mouse model of Pompe disease, which may lead to therapies for other enzyme deficiencies.[16]
Interest in glucagon treatment for McArdle disease has developed, but a study by Day and Mastaglia showed no benefit over placebo.[17]

Diet and Activity

Diet

A high-protein diet may increase exercise tolerance in some cases, although this practice is controversial.

Activity

Avoidance of intense physical activity usually ameliorates symptoms.

Author

Isaac Omolade Ogunmola, MBBS Resident Physician, Department of Internal Medicine, Einstein Medical Center

Isaac Omolade Ogunmola, MBBS is a member of the following medical societies: European Society of Cardiology, Medical and Dental Council of Nigeria

Disclosure: Nothing to disclose.

Coauthor(s)

Catherine Anastasopoulou, MD, PhD, FACE Associate Professor of Medicine, The Steven, Daniel and Douglas Altman Chair of Endocrinology, Sidney Kimmel Medical College of Thomas Jefferson University; Einstein Endocrine Associates, Einstein Medical Center

Catherine Anastasopoulou, MD, PhD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American Society for Bone and Mineral Research, Endocrine Society, Philadelphia Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kent Wehmeier, MD Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine

Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for Physician Leadership, American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society, International Society for Clinical Densitometry, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

David M Klachko, MD, MEd Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Missouri-Columbia School of Medicine

David M Klachko, MD, MEd is a member of the following medical societies: Alpha Omega Alpha, Missouri State Medical Association, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, Endocrine Society, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Wayne E Anderson, DO, FAHS, FAAN Assistant Professor of Internal Medicine/Neurology, College of Osteopathic Medicine of the Pacific Western University of Health Sciences; Clinical Faculty in Family Medicine, Touro University College of Osteopathic Medicine; Clinical Instructor, Departments of Neurology and Pain Management, California Pacific Medical Center

Wayne E Anderson, DO, FAHS, FAAN is a member of the following medical societies: American Academy of Neurology, American Headache Society, California Medical Association, California Neurology Society, International Headache Society, San Francisco Medical Society, San Francisco Neurological Society

Disclosure: Nothing to disclose.

Llavero F, Arrazola Sastre A, Luque Montoro M, Gálvez P, Lacerda HM, Parada LA, et al. McArdle Disease: New Insights into Its Underlying Molecular Mechanisms. Int J Mol Sci. 2019 Nov 25. 20 (23):5919. [QxMD MEDLINE Link].
Kemp GJ, Tonon C, Malucelli E, et al. Cytosolic pH buffering during exercise and recovery in skeletal muscle of patients with McArdle's disease. Eur J Appl Physiol. 2009 Mar. 105(5):687-94. [QxMD MEDLINE Link].
Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. Cochrane Database Syst Rev. 2011 Dec 7. 12:CD007931. [QxMD MEDLINE Link].
Chéraud C, Froissart R, Lannes B, Echaniz-Laguna A. Novel variant in the PYGM gene causing late-onset limb-girdle myopathy, ptosis, and camptocormia. Muscle Nerve. 2018 Jan. 57 (1):157-160. [QxMD MEDLINE Link].
Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010 Nov. 81 (11):1182-8. [QxMD MEDLINE Link].
Bollig G. McArdle's disease (glycogen storage disease type V) and anesthesia--a case report and review of the literature. Paediatr Anaesth. 2013 Sep. 23(9):817-23. [QxMD MEDLINE Link].
Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010 Nov. 81 (11):1182-8. [QxMD MEDLINE Link].
Orngreen MC, Jeppesen TD, Andersen ST, et al. Fat metabolism during exercise in patients with McArdle disease. Neurology. 2009 Feb 24. 72(8):718-24. [QxMD MEDLINE Link].
Kitaoka Y. McArdle Disease and Exercise Physiology. Biology (Basel). 2014 Feb 25. 3(1):157-66. [QxMD MEDLINE Link]. [Full Text].
Porcelli S, Marzorati M, Belletti M, Bellistri G, Morandi L, Grassi B. The "second wind" in McArdle's disease patients during a second bout of constant work rate submaximal exercise. J Appl Physiol (1985). 2014 May 1. 116 (9):1230-7. [QxMD MEDLINE Link].
Jones DM, Lopes L, Quinlivan R, Elliott PM, Khanji MY. Cardiac manifestations of McArdle disease. Eur Heart J. 2019 Jan 21. 40 (4):397-398. [QxMD MEDLINE Link].
Bruno C, Bertini E, Santorelli FM. HyperCKemia as the only sign of McArdle''s disease in a child. J Child Neurol. 2000 Feb. 15(2):137-8. [QxMD MEDLINE Link].
Felice KJ, Grunnet ML, Sima AA. Selective atrophy of type 1 muscle fibers in McArdle's disease. Neurology. 1996 Aug. 47(2):581-3. [QxMD MEDLINE Link].
Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry. 2008 Dec. 79(12):1359-63. [QxMD MEDLINE Link].
Zingone A, Hiraiwa H, Pan CJ. Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem. 2000 Jan 14. 275(2):828-32. [QxMD MEDLINE Link].
Bijvoet AG, Van Hirtum H, Vermey M. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol. 1999 Nov. 189(3):416-24. [QxMD MEDLINE Link].
Day TJ, Mastaglia FL. Depot-glucagon in the treatment of McArdle''s disease. Aust N Z J Med. 1985 Dec. 15(6):748-50. [QxMD MEDLINE Link].
Andersen ST, Jeppesen TD, Taivassalo T, et al. Effect of changes in fat availability on exercise capacity in McArdle disease. Arch Neurol. 2009 Jun. 66(6):762-6. [QxMD MEDLINE Link].
Amato AA. Acid maltase deficiency and related myopathies. Neurol Clin. 2000 Feb. 18(1):151-65. [QxMD MEDLINE Link].
Aminoff MJ, ed. Electromyography in Clinical Practice. 3rd ed. New York, NY: Churchill Livingstone; 1998.
Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000 Jan. 105(1):e10. [QxMD MEDLINE Link].